BioWorld

Oct. 21, 2008

View Archived Issues

Adventrx Restructures to Focus Efforts on ANX-530 and ANX-514

A year after lead product CoFactor (ANX-510) failed a Phase IIb trial, Adventrx Pharmaceuticals Inc. is restructuring to focus on its chemotherapy emulsion products, ANX-530 and ANX-514. (BioWorld Today) Read More

'Not a Slam-Dunk': FDA Panel to Review New Version of Myozyme

Read More

Study Describes Partner in Crime for Bcr-Abl Kinase

Read More

Singapore's S*BIO Adds $26M for Phase II Studies in Cancer

Read More

Other News To Note

Read More

Clinic Roundup

Read More